Moreover, among A1 patients with a tumor size >5 cm (panel d), those carrying a KIT or PDGFRA mutation (n = 11) had a worse prognosis than the WT (n = 3), the 2-year RFS rates being 58 and 100 % respectively. This evidence concerns the gene PDGFRA and neoplasm.